Cytokinetics INC Form 4 insider transactions

Cytokinetics EVP Andrew Callos sold 1,709 shares of common stock for $61.03 per share under a pre-arranged trading plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold a portion of his common stock holdings on March 5, 2026.

Cytokinetics Director B. Lynne Parshall sold 5,000 shares of common stock at $61.21 per share in a pre-planned transaction.

Cytokinetics' Chief Commercial Officer, Andrew Callos, exercised stock options and simultaneously sold an equal number of shares under a pre-arranged 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold an equal number of shares under a pre-arranged plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, exercised stock options and subsequently sold an equal number of shares in a pre-planned transaction.

Cytokinetics Director James M. Daly acquired 197 shares of common stock at $63.44 per share, opting for equity in lieu of a cash retainer.

Cytokinetics Director Nancy Wysenski acquired 98 shares of common stock at $63.44 per share, increasing her direct beneficial ownership to 30,971 shares.

Cytokinetics Director Wendell Wierenga acquired 98 shares of common stock at $63.44 per share as part of an equity compensation plan.

Cytokinetics Director Edward M. Kaye MD acquired 197 shares of common stock at $63.44 per share as part of an equity compensation plan.

Cytokinetics Director John T. Henderson acquired 334 shares of common stock at $63.44 per share as equity compensation.

Cytokinetics director Robert Arthur Harrington acquired 197 shares of common stock at $63.44 per share on January 15, 2026, as part of an equity compensation plan.

Cytokinetics' EVP, Chief Commercial Officer Andrew Callos, exercised stock options and subsequently sold an equal number of common shares, as per a Rule 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, reported future planned sales of common stock following option exercises under a 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer Andrew Callos, sold 1,809 shares of common stock for $62.44 per share under a Rule 10b5-1 plan.

Cytokinetics CEO Robert I. Blum increased his beneficial ownership through performance share awards, partially offset by tax-related share withholding.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, increased his direct beneficial ownership of common stock through performance share awards.

Cytokinetics' Chief Commercial Officer, Andrew Callos, reported the acquisition of performance shares and a tax-related disposition, resulting in a net increase in his direct beneficial ownership.

CYTOKINETICS' EVP and CFO, Sung Lee, reported the acquisition of performance shares and a sale for tax withholding purposes.

Cytokinetics' President and CEO, Robert I. Blum, exercised stock options and adjusted his beneficial ownership of common stock through pre-planned transactions.

Cytokinetics Director Wendell Wierenga exercised stock options and subsequently sold a portion of his common stock holdings under a 10b5-1 plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, sold 2,200 shares of common stock after exercising incentive stock options.

Cytokinetics EVP and Chief Commercial Officer Andrew Callos exercised stock options and subsequently sold an equal number of common shares under a Rule 10b5-1 plan.

Cytokinetics' EVP and Chief Commercial Officer Andrew Callos exercised stock options and subsequently sold an equal number of common shares under a Rule 10b5-1 plan.

Cytokinetics' EVP and CFO, Sung Lee, sold 1,560 shares of common stock to cover tax obligations related to vested performance stock units.

Cytokinetics' Chief Commercial Officer, Andrew Callos, sold 1,368 shares of common stock to cover tax withholding obligations related to vested performance stock units.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, has filed a Form 4 reporting a planned sale of 2,058 shares of common stock on December 3, 2025, to cover tax withholding obligations related to PSUs vested in December 2024.

Cytokinetics CEO Robert I. Blum reported the disposition of 5,930 common shares at $65.02 each to cover tax liabilities, as part of a pre-arranged plan.

Cytokinetics Director John T. Henderson exercised stock options and sold 8,750 shares of common stock under a Rule 10b5-1 plan.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and subsequently sold the acquired common stock in a pre-planned transaction.